🔎 Trials Near Me

Utama › Adenokarsinoma Esofagus › Utah

Kajian klinikal Adenokarsinoma Esofagus di Utah

5 kajian untuk Adenokarsinoma Esofagus sedang mencari peserta di lokasi di Utah.

Bandar di Utah

Teks kajian rasmi (Bahasa Inggeris)

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

  • Farmington Health Center, Farmington
  • University of Utah Sugarhouse Health Center, Salt Lake City
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06203600

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  • Farmington Health Center, Farmington
  • University of Utah Sugarhouse Health Center, Salt Lake City
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05677490

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  • START Mountain Region, LLC, West Valley City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07277413

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT06330064

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

  • Huntsman Cancer Institute, University of Utah, Salt Lake City
  • START Mountain Region, LLC., West Valley City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jul 2026 · NCT06657144

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.